Maximizing Therapeutic Succes: Choosing the Right Oligonucleotide, Delivery Vehicle & Administration Route

• Shuttle peptide platform: Efficient endosomal escape driving the development of PMO-based therapeutics
• Development of a non-surgical therapeutic for basal cell carcinoma administered by intralesional injection
• Efficient delivery to airway epithelial cells, advancing inhaled PMO therapies for muco-obstructive lung diseases

Speakers:

David Guay

Vice President, Innovation & Technology

Feldan Therapeutics